A61K 40/4219
Receptors for chemokines
Official title: {Receptors for chemokines}
A61K40/4219 (Receptors for chemokines) appears on 32 US grants and 90 published applications in this corpus.
Search patents in A61K- Granted patents
- 32
- Published applications
- 90
- Assignees
- 73
- Inventors
- 212
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 1 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 6 |
| 2019 | 1 | 5 |
| 2020 | 3 | 10 |
| 2021 | 4 | 10 |
| 2022 | 4 | 7 |
| 2023 | 5 | 5 |
| 2024 | 6 | 18 |
| 2025 | 4 | 15 |
| 2026 | 4 | 8 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Chimeric antigen receptor T cell therapy19 May 2026US 12,630,603 B2Kite Pharma, Inc.
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies24 Mar 2026US 12,584,138 B2ImmunityBio, Inc.
- Chemokine responsive activated natural killer cells with secondary homing activation for verified targets3 Feb 2026US 12,540,170 B2ImmunityBio, Inc.
- Non-signaling HIV fusion inhibitors and methods of use thereof16 Dec 2025US 12,497,623 B2The Trustees of the University of Pennsylvania
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies20 Aug 2026US 2026/0242801 A1ImmunityBio, Inc.
- Ccr9 targeting moiety for the treatment of ccr9-positive cancer13 Aug 2026US 2026/0232732 A1
- Non-Signaling HIV Fusion Inhibitors And Methods Of Use Thereof18 Jun 2026US 2026/0167978 A1The Trustees of the University of Pennsylvania
- T cells modified to express mutated cxcr4 or partially deleted and uses thereof11 Jun 2026US 2026/0159572 A1Centre National de la Recherche Scientifique (CNRS)
Most cited
By later US patents
- Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same21US 9,393,268 B2Thomas Jefferson University · 2016
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies13US 10,960,024 B2NantKwest, Inc. · 2021
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies6US 11,058,723 B2NantKwest, Inc. · 2021
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies6US 11,129,850 B2ImmunityBio, Inc. · 2021
- NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors5US 10,813,952 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2020